The US Food and Drug Administration started 2025 with just more than 60 novel candidates under review, according to the Pink Sheet US FDA Performance Tracker’s User Fee Goal Dates tracker.
Novel Agents Up For US FDA Approval In 2025
CBER has at least 14 and CDER another 10 novel biologics among the more than 60 candidates with a user fee goal in 2025.
